NasdaqGS - Delayed Quote • USD
Alkermes plc (ALKS)
At close: April 18 at 4:00 PM EDT
Pre-Market: 4:32 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | 0.62 | 0.76 | 2.79 | 2.68 |
| Low Estimate | 0.53 | 0.71 | 2.7 | 2.35 |
| High Estimate | 0.68 | 0.8 | 2.9 | 3.26 |
| Year Ago EPS | 0.01 | 0.55 | 1.44 | 2.79 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 8 | 12 | 11 |
| Avg. Estimate | 366.89M | 390.9M | 1.53B | 1.54B |
| Low Estimate | 349.9M | 385.67M | 1.46B | 1.43B |
| High Estimate | 374.7M | 395.79M | 1.56B | 1.74B |
| Year Ago Sales | 287.6M | 617.4M | 1.66B | 1.53B |
| Sales Growth (year/est) | 27.60% | -36.70% | -8.30% | 0.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.01 | 0.46 | 0.44 | 0.51 |
| EPS Actual | 0.01 | 0.55 | 0.64 | 0.22 |
| Difference | 0.02 | 0.09 | 0.2 | -0.29 |
| Surprise % | 200.00% | 19.60% | 45.50% | -56.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.62 | 0.76 | 2.79 | 2.68 |
| 7 Days Ago | 0.67 | 0.78 | 2.79 | 2.68 |
| 30 Days Ago | 0.69 | 0.79 | 2.79 | 2.7 |
| 60 Days Ago | 0.67 | 0.75 | 2.78 | 2.68 |
| 90 Days Ago | 0.49 | 0.56 | 2.32 | 2.55 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | 1 | 1 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | ALKS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 6,100.00% | -- | -- | 0.80% |
| Next Qtr. | 38.20% | -- | -- | 9.60% |
| Current Year | 93.80% | -- | -- | 4.50% |
| Next Year | -3.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 24.80% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 3.24% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 4/19/2024 |
| Maintains | Jefferies: Buy to Buy | 4/9/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 4/1/2024 |
| Initiated | Baird: Outperform | 3/19/2024 |
| Downgrade | UBS: Neutral to Sell | 2/20/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/16/2024 |
Related Tickers
NBIX Neurocrine Biosciences, Inc.
132.54
-0.52%
IRWD Ironwood Pharmaceuticals, Inc.
7.60
-0.65%
AMPH Amphastar Pharmaceuticals, Inc.
38.65
-3.50%
SUPN Supernus Pharmaceuticals, Inc.
28.87
-0.45%
INDV Indivior PLC
18.76
-2.60%
EOLS Evolus, Inc.
11.56
-0.69%
PCRX Pacira BioSciences, Inc.
26.10
-2.50%
PETQ PetIQ, Inc.
16.03
+0.63%
ALIM Alimera Sciences, Inc.
3.4400
-3.10%
ESAIY Eisai Co., Ltd.
9.33
-2.30%